Recently, at the release of " China Future Unicorn Enterprises Research Report 2025" by The Great Wall Strategy Consultants (GEI) in Shenzhen, Biomissile Pharmaceuticals Co., Ltd. was selected one of the enterprises nationwide to receive this honor.
About the GEI China Future Unicorn Enterprise Research Report 2025
GEI has been a pioneer in unicorn and future unicorn enterprise research in China, releasing authoritative rankings since 2016. Today, GEI China Future Unicorn Enterprises Research Report stands as an industry benchmark for identifying high-growth companies in China. This report was officially released on December 13, 2025, at the 2025 Enterprise Science and Technology Innovation Development Forum in Shenzhen.
Future Unicorn Enterprise Criteria
The evaluation is based on the national recommended standard Guidelines for Classification of High-Growth Enterprises (GB/T 41464-2022), co-developed by GEI and the China National Institute of Standardization. Key criteria include:
1. A legal entity registered in China;
2. Established for no more than nine years;
3. Received private equity investment and unlisted on any stock exchange;
4. Valuation of USD $100 million within five years of establishment, or USD $500 million within 5-9 years.
This standard serves as a vital framework for evaluating high-growth companies and shaping supportive policies across China.
About Biomissile Pharmaceuticals
Biomissile Pharmaceuticals is a clinical-stage biotech company developing fully human domain antibody (UDABTM)-based multi-specific antibodies (UDAB-MTM) for solid tumors, autoimmune diseases, and infectious diseases. Leveraging these proprietary platform technologies, we have developed our UDAB-M Immune Cell Engager (ICE) platform and built a highly differentiated pipeline that selectively activates both NK and T cells, effectively targeting cold tumors, including TAA-low and ADC-resistant solid tumors. In addition to oncology, UDAB-M molecules have been successfully expanded into autoimmune diseases, where they have demonstrated best-in-class potential for B cell depletion and multi-pathway immune blockade.
Link to the news in Chinese: